Gut microbes as a therapeutic armory

Q3 Pharmacology, Toxicology and Pharmaceutics Drug Discovery Today: Disease Models Pub Date : 2018-06-01 DOI:10.1016/j.ddmod.2019.08.007
Neerupma Bhardwaj , Naama Geva-Zatorsky
{"title":"Gut microbes as a therapeutic armory","authors":"Neerupma Bhardwaj ,&nbsp;Naama Geva-Zatorsky","doi":"10.1016/j.ddmod.2019.08.007","DOIUrl":null,"url":null,"abstract":"<div><p><span>Gut microbes have recently been appreciated to be a possible source of future therapeutics. They have been shown to be associated with a variety of diseases from diverse etiologies. The microbiome can change during the progression of some diseases, and in some cases is linked with disease severity. Following these findings, fecal transplantation has been integrated into treating </span><em>Clostridium difficile</em><span> infections with high success rates. These results have become a driving force for studies demonstrating the therapeutic potential of gut bacteria<span> in other clinical indications. However, extensive research and clinical trials are still needed in order to reach the goal of using defined live microbial therapeutics for treatment. A mechanistic understanding of the effects of individual strains and bacterial consortia on the mammalian host, their colonization dynamics, and long-term impact, on both the gut ecosystem and their host, is thus required. In this review, we discuss the potential of individual bacteria or bacterial consortia in therapeutics, mouse models for such studies, and the future directions for deriving valuable therapeutics from the gut microbial armory.</span></span></p></div>","PeriodicalId":39774,"journal":{"name":"Drug Discovery Today: Disease Models","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ddmod.2019.08.007","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Discovery Today: Disease Models","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1740675719300167","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 3

Abstract

Gut microbes have recently been appreciated to be a possible source of future therapeutics. They have been shown to be associated with a variety of diseases from diverse etiologies. The microbiome can change during the progression of some diseases, and in some cases is linked with disease severity. Following these findings, fecal transplantation has been integrated into treating Clostridium difficile infections with high success rates. These results have become a driving force for studies demonstrating the therapeutic potential of gut bacteria in other clinical indications. However, extensive research and clinical trials are still needed in order to reach the goal of using defined live microbial therapeutics for treatment. A mechanistic understanding of the effects of individual strains and bacterial consortia on the mammalian host, their colonization dynamics, and long-term impact, on both the gut ecosystem and their host, is thus required. In this review, we discuss the potential of individual bacteria or bacterial consortia in therapeutics, mouse models for such studies, and the future directions for deriving valuable therapeutics from the gut microbial armory.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
肠道微生物作为治疗的军械库
肠道微生物最近被认为是未来治疗的可能来源。它们已被证明与各种病因的各种疾病有关。在某些疾病的进展过程中,微生物群会发生变化,在某些情况下,与疾病的严重程度有关。根据这些发现,粪便移植已被纳入治疗艰难梭菌感染的高成功率。这些结果已经成为证明肠道细菌在其他临床适应症中的治疗潜力的研究的推动力。然而,为了达到使用已定义的活微生物疗法进行治疗的目标,仍需要广泛的研究和临床试验。因此,需要对单个菌株和细菌群落对哺乳动物宿主的影响、它们的定植动态以及对肠道生态系统和宿主的长期影响有一个机制上的了解。在这篇综述中,我们讨论了单个细菌或细菌联合体在治疗中的潜力,这些研究的小鼠模型,以及从肠道微生物库中获得有价值的治疗方法的未来方向。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Drug Discovery Today: Disease Models
Drug Discovery Today: Disease Models Pharmacology, Toxicology and Pharmaceutics-Drug Discovery
自引率
0.00%
发文量
0
期刊介绍: Drug Discovery Today: Disease Models discusses the non-human experimental models through which inference is drawn regarding the molecular aetiology and pathogenesis of human disease. It provides critical analysis and evaluation of which models can genuinely inform the research community about the direct process of human disease, those which may have value in basic toxicology, and those which are simply designed for effective expression and raw characterisation.
期刊最新文献
Balanced actions of estradiol and progesterone—A new paradigm of women’s reproductive health Women’s reproductive system as balanced estradiol and progesterone actions—A revolutionary, paradigm-shifting concept in women’s health Influence of progestagens on bone health. Bone changes related to ovulatory disturbances and low progesterone levels Hereditary bullous diseases: current and innovative models to study the skin blistering disease epidermolysis bullosa The extent and causes of natural variation in menstrual cycles: Integrating empirically-based models of ovarian cycling into research on women’s health
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1